CA-OMNICELL
4.1.2021 14:02:10 CET | Business Wire | Press release
Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and supply chain solutions for health systems, today announced its intent to enter a new partnership with Guy’s and St Thomas’ NHS Foundation Trust, London to develop technology-enabled inventory optimization and intelligence services.
As part of a £10.5 million capital investment, the South East London Integrated Care System (ICS) will expand the deployment of Omnicell automation systems across six acute hospital sites. This also includes the opportunity for Omnicell and the Trust to launch a European-based technology-enabled intelligence center with the aim to deliver advanced analytics to manage supplies and medications. Combined with the expansion of Omnicell automated dispensing systems across the South East London hospitals, it is expected that this technology-enabled intelligence center will provide a high level of visibility and actionable insights for the South East London Integrated Care System to improve efficiency and patient safety.
The Integrated Care System includes two of the UK’s biggest hospital trusts, Guy’s and St Thomas’ NHS Foundation Trust and Kings College Hospital NHS Foundation Trust, as well as Lewisham and Greenwich NHS Trust. These Trusts are already using a mix of Omnicell’s XT supply and medication dispensing systems to manage clinical inventory and medications. The ICS successfully secured capital funding from the Department of Health Wave IV Estate Transformation Fund to undertake a regional supply chain transformation program.
By choosing Omnicell as its sole Inventory Management Solution, the Integrated Care System will be able to deliver consistency of practice and openly share data through a single instance based in the cloud. These systems, coupled with the expected technology-enabled intelligence centre based at Guy’s and St Thomas’, aim to provide total visibility of all medication and clinical inventory across the region. The solution will leverage the latest AI tools to provide real-time analytic support and system optimization. This will help reduce the risk of dispensing errors and help deliver the right medication, in the right place, at the right time.
Omnicell’s cloud-based intelligence, automation, and technology-enabled services are helping health systems across the globe to:
- support patient safety
- drive efficiencies
- reduce unnecessary and costly wastage
- allow healthcare professionals to increase their time for face-to-face patient care.
David Lawson, Chief Procurement Officer for Guy’s and St Thomas’, said: “We are delighted to join with Omnicell to bring this cutting-edge solution to the UK. The Trust has successfully deployed Omnicell systems for supplies and medication for over 10 years and the opportunity of this new intelligence offering alongside the expansion of Omnicell systems across South East London represents the next chapter in a successful long term partnership with Omnicell. Through this collaboration, South East London hopes to develop new AI tools to reduce variation between hospital sites and optimize system performance to allow for improved patient outcomes and operational efficiency at a regional level.”
Sara Dalmasso, vice president and general manager, International, at Omnicell said: “Expanding technology-enabled services and intelligence solutions reflects our ambition to deploy advanced analytic and optimization tools to support health systems across Europe. This new partnership with Guy’s and St Thomas’ also demonstrates that Omnicell is quickly becoming the go-to provider for regional medication and supply management solutions across the UK. We are hugely excited to be offered another opportunity to work with a likeminded partner who wants to reshape how automated inventory and medical supply management systems are viewed in the NHS and the wider European market. We share a goal of improving healthcare and patient safety, and I’m looking forward to working with Guy’s and St Thomas’ and South East London to support our joint vision.”
About Guy’s and St Thomas’ and South East London Integrated Care System
Guy’s and St Thomas’ provides 2.6 million patient contacts in acute and specialist hospital services and community services every year. As one of the biggest NHS trusts in the UK, with an annual turnover of almost £1.7 billion, we employ around 18,000 staff. To learn more, visit: www.guysandstthomas.nhs.uk
South East London Integrated Care System brings together local health and care organisations and local councils to re-design care and improve population health through shared leadership and collective action. It covers six London boroughs, Bexley, Bromley, Greenwich, Lambeth, Lewisham and Southwark, with 1.9 million patients. Priorities include reducing costs through provider collaboration and changing the way they work together to deliver transformation. To learn more, visit: https://www.ourhealthiersel.nhs.uk/
About Omnicell
Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 50,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com .
OMCL-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005125/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
Swiss Leader Leonteq Chooses ActiveViam to Deliver High‑Performance FRTB Risk Analytics10.2.2026 09:00:00 CET | Press release
ActiveViam, a global leader in real‑time, multidimensional risk analytics for capital markets, today announced that Leonteq, one of the leading Swiss providers of structured products, has implemented Atoti to calculate Market Risk Capital Charges under the Standardized Approach of the Fundamental Review of the Trading Book (SA-FRTB). ActiveViam’s flagship product, Atoti, is being used by Leonteq as its FRTB reporting solution to the Swiss Financial Market Supervisory Authority (FINMA). Switzerland implemented FRTB for its banks on 1st January 2025 and FINMA recently extended its scope to include Leonteq. When the FRTB implementation deadlines became clear, Leonteq evaluated several vendors for a solution that could integrate with its existing pricing engines. After a detailed assessment, it selected Atoti. The solution provides dashboards and preconfigured reports that meet FINMA’s requirements, along with analytics aligned to the ISDA Unit Tests and additional capabilities such as wha
Bending Spoons offers €1.5 million in tech scholarships through new Fellowship program10.2.2026 09:00:00 CET | Press release
Today Bending Spoons announced the launch of the Bending Spoons Fellowship, committing up to €1.5 million to support Europe’s most outstanding computer science students through the program. The fellowship will award ten scholarships—each worth €50,000 per year and renewable for up to three years—to high-achieving university students in computer science and related fields across Europe and the UK. “We think exceptional talent deserves exceptional opportunities,” said Costanza Mazzei, the Bending Spoons talent manager leading the program. “With the Bending Spoons Fellowship, we aim to give Europe’s most driven students the freedom, resources, and guidance to reach the highest levels of excellence.” In addition to financial support, Fellowship participants will benefit from individual mentorship and may choose to participate in an optional paid summer internship at Bending Spoons. The fellowship is the latest initiative from Bending Spoons to support emerging technical talent. It builds o
Ralph Haupter Joins Warburg Pincus as an External Senior Advisor10.2.2026 09:00:00 CET | Press release
Seasoned Technology Executive to Support European Technology Group Warburg Pincus, the pioneer of private equity global growth investing, today announced that Ralph Haupter will serve as an External Senior Advisor to its European Technology team. Mr. Haupter, Executive Vice President and Chief Revenue Officer for Small Medium Enterprises and Channel (SME&C) at Microsoft, will take on this personal engagement to help the firm identify and evaluate new investment opportunities across the software and technology sectors. He will also play an active role in value creation across the firm’s existing portfolio. Mr. Haupter brings over 25 years of global operating experience and deep expertise in technology innovation and transformation. At Microsoft, he leads a global organization that works with the company’s extensive partner ecosystem to empower small and medium businesses worldwide. Previously, he held senior leadership roles across Europe, Asia, and the Americas, including President of
CapVest Enters Exclusive Discussions With HLD on the Proposed Acquisition of TSG10.2.2026 09:00:00 CET | Press release
HLD and management to retain significant minority stakes in TSG, partnering with CapVest on a shared vision to lead the company into its next phase of global growth CapVest Partners LLP (“CapVest”), a leading New York and London based investment firm, and HLD, the entrepreneurial European investment group, have entered exclusive discussions on CapVest’s proposed acquisition of a majority stake in TSG, a European leader in technical services for critical energy infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210375858/en/ Headquartered in Paris, France, TSG is a European leader in technical services for the energy industry with a pan-European footprint in over 30 countries and employing over 7,000 people. Originally focused on fuel station and private fleet energy infrastructure and systems, since HLD’s acquisition of the company in 2020 TSG has undergone significant transformation as a primary enabler of th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom